Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
J Geriatr Phys Ther ; 44(1): 18-24, 2021.
Article in English | MEDLINE | ID: mdl-31021896

ABSTRACT

BACKGROUND AND PURPOSE: The purposes of this study were to examine (1) differences in mood and motivation among older adults after the completion of 6 minutes of self-paced walking (6MW) and (2) the relationship between pace and magnitude of mood change. METHODS: Eleven participants completed 3 days of testing where energy, fatigue, tension, depression, confusion, mental and physical energy, and motivation to perform mental tasks were measured before and after the 6MW. A repeated-measures analysis of variance was used to examine changes in mood and motivation, and a bivariate Pearson correlation was used to determine relationships between pace and magnitude of changes in mood. RESULTS: Faster pace was associated with significant improvements (P < .05) in fatigue, energy, tension, confusion, total mood disturbance, state mental fatigue, and state physical energy. A significant relationship was noted between pace and changes in energy, fatigue, state mental and physical energy, and fatigue in the expected direction. DISCUSSION: Results indicate that mood is influenced by pace of the activity. Findings suggest that even 6 minutes of physical activity can improve moods, which may impact how physical therapists approach prescribing exercise to older adults.


Subject(s)
Affect/physiology , Exercise/physiology , Exercise/psychology , Aged , Aged, 80 and over , Cross-Over Studies , Depression/physiopathology , Fatigue/physiopathology , Female , Humans , Male , Mental Health , Motivation , Pilot Projects
2.
J Exp Biol ; 223(Pt 20)2020 10 29.
Article in English | MEDLINE | ID: mdl-32958522

ABSTRACT

Despite its common use as a laboratory model, little is known about the in vivo forces and moments applied to the bovine caudal intervertebral disc. Such aspects are crucial, as intervertebral disc tissue is known to remodel in response to repeated loading. We hypothesized that the magnitude of loading from muscle contraction during a typical lateral bending motion varies between caudal levels and is accompanied by variations in tissue microstructure. This hypothesis was tested by estimating level-wise forces and bending moments using two independent approaches: a dynamic analytical model of the motion and analysis of muscle cross-sections obtained via computed tomography. Microstructure was assessed by measuring the collagen fiber crimp period in the annulus fibrosus, and composition was assessed via quantitative histology. Both the analytical model and muscle cross-sections indicated peak bending moments of over 3 N m and peak compressive force of over 125 N at the c1c2 level, decreasing distally. There was a significant downward trend from proximal to distal in the outer annulus fibrosus collagen crimp period in the anterior and posterior regions only, suggesting remodeling in response to the highest lateral bending moments. There were no observed trends in composition. Our results suggest that although the proximal discs in the bovine tail are subjected to forces and moments from muscle contraction that are comparable (relative to disc size) to those acting on human lumbar discs, the distal discs are not. The resulting pattern of microstructural alterations suggests that level-wise differences should be considered when using bovine discs as a research model.


Subject(s)
Intervertebral Disc , Animals , Biomechanical Phenomena , Cattle , Collagen , Humans , Lumbar Vertebrae , Mechanical Phenomena , Stress, Mechanical , Tomography, X-Ray Computed
5.
J Med Chem ; 62(4): 1793-1802, 2019 02 28.
Article in English | MEDLINE | ID: mdl-30688459

ABSTRACT

Protein tyrosine phosphatase SHP2 is an oncoprotein associated with cancer as well as a potential immune modulator because of its role in the programmed cell death PD-L1/PD-1 pathway. In the preceding manuscript, we described the optimization of a fused, bicyclic screening hit for potency, selectivity, and physicochemical properties in order to further expand the chemical diversity of allosteric SHP2 inhibitors. In this manuscript, we describe the further expansion of our approach, morphing the fused, bicyclic system into a novel monocyclic pyrimidinone scaffold through our understanding of SAR and use of structure-based design. These studies led to the identification of SHP394 (1), an orally efficacious inhibitor of SHP2, with high lipophilic efficiency, improved potency, and enhanced pharmacokinetic properties. We also report other pyrimidinone analogues with favorable pharmacokinetic and potency profiles. Overall, this work improves upon our previously described allosteric inhibitors and exemplifies and extends the range of permissible chemical templates that inhibit SHP2 via the allosteric mechanism.


Subject(s)
Aminopyridines/therapeutic use , Antineoplastic Agents/therapeutic use , Enzyme Inhibitors/therapeutic use , Neoplasms/drug therapy , Protein Tyrosine Phosphatase, Non-Receptor Type 11/antagonists & inhibitors , Pyrimidinones/therapeutic use , Administration, Oral , Allosteric Regulation , Allosteric Site , Aminopyridines/chemical synthesis , Aminopyridines/pharmacokinetics , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacokinetics , Cell Line, Tumor , Crystallography, X-Ray , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacokinetics , Female , Humans , Male , Mice, Inbred C57BL , Molecular Structure , Protein Tyrosine Phosphatase, Non-Receptor Type 11/chemistry , Pyrimidinones/chemical synthesis , Pyrimidinones/pharmacokinetics , Structure-Activity Relationship , Xenograft Model Antitumor Assays
6.
J Med Chem ; 62(4): 1781-1792, 2019 02 28.
Article in English | MEDLINE | ID: mdl-30688462

ABSTRACT

SHP2 is a nonreceptor protein tyrosine phosphatase within the mitogen-activated protein kinase (MAPK) pathway controlling cell growth, differentiation, and oncogenic transformation. SHP2 also participates in the programed cell death pathway (PD-1/PD-L1) governing immune surveillance. Small-molecule inhibition of SHP2 has been widely investigated, including in our previous reports describing SHP099 (2), which binds to a tunnel-like allosteric binding site. To broaden our approach to allosteric inhibition of SHP2, we conducted additional hit finding, evaluation, and structure-based scaffold morphing. These studies, reported here in the first of two papers, led to the identification of multiple 5,6-fused bicyclic scaffolds that bind to the same allosteric tunnel as 2. We demonstrate the structural diversity permitted by the tunnel pharmacophore and culminated in the identification of pyrazolopyrimidinones (e.g., SHP389, 1) that modulate MAPK signaling in vivo. These studies also served as the basis for further scaffold morphing and optimization, detailed in the following manuscript.


Subject(s)
Enzyme Inhibitors/pharmacology , Heterocyclic Compounds, 2-Ring/pharmacology , Protein Tyrosine Phosphatase, Non-Receptor Type 11/antagonists & inhibitors , Pyrazoles/pharmacology , Pyrimidinones/pharmacology , Allosteric Regulation , Allosteric Site , Animals , Cell Line, Tumor , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/metabolism , Heterocyclic Compounds, 2-Ring/chemical synthesis , Heterocyclic Compounds, 2-Ring/metabolism , Humans , MAP Kinase Signaling System/drug effects , Male , Mice, Inbred C57BL , Microsomes, Liver/metabolism , Molecular Docking Simulation , Molecular Structure , Protein Binding , Protein Tyrosine Phosphatase, Non-Receptor Type 11/chemistry , Protein Tyrosine Phosphatase, Non-Receptor Type 11/metabolism , Pyrazoles/chemical synthesis , Pyrazoles/metabolism , Pyrimidinones/chemical synthesis , Pyrimidinones/metabolism , Rats, Sprague-Dawley , Structure-Activity Relationship
7.
J Allied Health ; 47(4): 282-288, 2018.
Article in English | MEDLINE | ID: mdl-30508840

ABSTRACT

AIMS: Graduate education in the healthcare professions can be stressful and mentally taxing. The objective of this study was to identify differences in health and health-related behaviors among graduate allied health students based on sex and curriculum stage (i.e., didactic or clinical education). METHODS: Participants (n=77) were assessed for body fat, BMI, resting metabolic rate (RMR), and peripheral arterial-venous O2 (AVO2), as well as a series of cognitive tasks and self-reported health and health-related behaviors. Independent sample t-tests and tests of proportions were used to assess differences between groups. RESULTS: There was no evidence that the didactic and clinical students were meaningfully different upon entering their programs. Didactic students reported significantly higher tension/anxiety, depression, anger, confusion, fatigue, total mood disturbance, trait mental fatigue, total intensity of mental work performed, and time spent sitting (p<0.05). Didactic students also reported significantly lower RMR (p=0.033), but not after normalizing for fat-free mass. Males reported lower intensity of mental work performed on non-work days compared to females (p=0.009). CONCLUSIONS: Findings indicate students in didactic stages have worse mood and decreased health relative to their counterparts in clinical stages. Opportunities exist to integrate physical and mental health-related education, resources, and self-management programming into graduate allied health curricula to improve wellness among students.


Subject(s)
Allied Health Personnel , Health Status Indicators , Adult , Cross-Sectional Studies , Education, Graduate , Female , Humans , Male , Students, Health Occupations
8.
J Med Chem ; 61(24): 11021-11036, 2018 12 27.
Article in English | MEDLINE | ID: mdl-30407821

ABSTRACT

Spinal muscular atrophy (SMA), a rare neuromuscular disorder, is the leading genetic cause of death in infants and toddlers. SMA is caused by the deletion or a loss of function mutation of the survival motor neuron 1 (SMN1) gene. In humans, a second closely related gene SMN2 exists; however it codes for a less stable SMN protein. In recent years, significant progress has been made toward disease modifying treatments for SMA by modulating SMN2 pre-mRNA splicing. Herein, we describe the discovery of LMI070/branaplam, a small molecule that stabilizes the interaction between the spliceosome and SMN2 pre-mRNA. Branaplam (1) originated from a high-throughput phenotypic screening hit, pyridazine 2, and evolved via multiparameter lead optimization. In a severe mouse SMA model, branaplam treatment increased full-length SMN RNA and protein levels, and extended survival. Currently, branaplam is in clinical studies for SMA.


Subject(s)
Brain/drug effects , ERG1 Potassium Channel/metabolism , Muscular Atrophy, Spinal/drug therapy , Pyridazines/chemistry , Administration, Oral , Animals , Brain/metabolism , Cell Line , Crystallography, X-Ray , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical/methods , ERG1 Potassium Channel/antagonists & inhibitors , Humans , Mice, Inbred C57BL , Motor Neurons/drug effects , Muscular Atrophy, Spinal/genetics , Pyridazines/pharmacology , Quantitative Structure-Activity Relationship , RNA Splicing , Rats, Sprague-Dawley , Survival of Motor Neuron 1 Protein/genetics , Survival of Motor Neuron 1 Protein/metabolism , Survival of Motor Neuron 2 Protein/genetics
9.
Invest Ophthalmol Vis Sci ; 59(5): 1704-1716, 2018 04 01.
Article in English | MEDLINE | ID: mdl-29610853

ABSTRACT

Purpose: The nitric oxide/soluble guanylate cyclase/protein kinase G (NO/sGC/PKG) is known to be involved in the regulation of intraocular pressure (IOP) and may be dysregulated in glaucoma. The purpose is to demonstrate that the sGC activator MGV354 lowers IOP in a monkey model of glaucoma and could be considered as a possible new clinical drug candidate. Methods: Changes to cGMP were assessed in primary human trabecular meshwork (hNTM) cells and binding studies were conducted using human sGC full-length protein. Ocular safety tolerability, exposure, and efficacy studies were conducted in rabbit and monkey models following topical ocular dosing of MGV354. Results: sGC was highly expressed in the human and cynomolgus monkey outflow pathways. MGV354 had a 7-fold greater Bmax to oxidized sGC compared to that of reduced sGC and generated an 8- to 10-fold greater cGMP compared to that of a reduced condition in hTM cells. A single topical ocular dose with MGV354 caused a significant dose-dependent reduction of 20% to 40% (versus vehicle), lasting up to 6 hours in pigmented rabbits and 24 hours postdose in a cynomolgus monkey model of glaucoma. The MGV354-induced IOP lowering was sustained up to 7 days following once-daily dosing in a monkey model of glaucoma and was greater in magnitude compared to Travatan (travoprost)-induced IOP reduction. Mild to moderate ocular hyperemia was the main adverse effect noted. Conclusions: MGV354 represents a novel class of sGC activators that can lower IOP in preclinical models of glaucoma. The potential for sGC activators to be used as effective IOP-lowering drugs in glaucoma patients could be further determined in clinical studies.


Subject(s)
Antihypertensive Agents/pharmacology , Enzyme Activators/pharmacology , Glaucoma/drug therapy , Intraocular Pressure/drug effects , Piperidines/pharmacology , Pyrazoles/pharmacology , Pyridines/pharmacology , Soluble Guanylyl Cyclase/metabolism , Administration, Ophthalmic , Animals , Antihypertensive Agents/administration & dosage , Cells, Cultured , Cyclic GMP/metabolism , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Enzyme Activators/administration & dosage , Glaucoma/physiopathology , Humans , Immunohistochemistry , Macaca fascicularis , Ocular Hypotension/drug therapy , Ophthalmic Solutions , Piperidines/administration & dosage , Pyrazoles/administration & dosage , Pyridines/administration & dosage , Rabbits , Trabecular Meshwork/metabolism
10.
J Med Chem ; 61(6): 2552-2570, 2018 03 22.
Article in English | MEDLINE | ID: mdl-29498522

ABSTRACT

Soluble guanylate cyclase (sGC), the endogenous receptor for nitric oxide (NO), has been implicated in several diseases associated with oxidative stress. In a pathological oxidative environment, the heme group of sGC can be oxidized becoming unresponsive to NO leading to a loss in the ability to catalyze the production of cGMP. Recently a dysfunctional sGC/NO/cGMP pathway has been implicated in contributing to elevated intraocular pressure associated with glaucoma. Herein we describe the discovery of molecules specifically designed for topical ocular administration, which can activate oxidized sGC restoring the ability to catalyze the production of cGMP. These efforts culminated in the identification of compound (+)-23, which robustly lowers intraocular pressure in a cynomolgus model of elevated intraocular pressure over 24 h after a single topical ocular drop and has been selected for clinical evaluation.


Subject(s)
Enzyme Activators/chemical synthesis , Enzyme Activators/therapeutic use , Glaucoma/drug therapy , Soluble Guanylyl Cyclase/drug effects , Administration, Ophthalmic , Administration, Topical , Animals , CHO Cells , Cricetinae , Cricetulus , Cyclic GMP/biosynthesis , Drug Discovery , Enzyme Activators/administration & dosage , Humans , Intraocular Pressure/drug effects , Macaca fascicularis , Ophthalmic Solutions , Oxidation-Reduction , Rabbits
11.
JOR Spine ; 1(4): e1038, 2018 Dec.
Article in English | MEDLINE | ID: mdl-31463453

ABSTRACT

Lumbar spinal column laxity contributes to instability, increasing the risk of low back injury and pain. Until the laxity increase due to the cyclic loads of daily living can be quantified, the associated injury risk cannot be predicted clinically. This work cyclically loaded 5-vertebra lumbar motion segments (7 skeletally-mature cervine specimens, 5 osteoporotic human cadaver specimens) for 20 000 cycles of low-load low-angle (15°) flexion. The normalized neutral zone lengths and slopes of the load-displacement hysteresis loops showed a similar increase in spinal column laxity across species. The intervertebral kinematics also changes with cyclic loading. Differences in the location and magnitude of surface strain on the vertebral bodies (0.34% ± 0.11% in the cervine specimens, and 3.13% ± 1.69% in the human cadaver specimens) are consistent with expected fracture modes in these populations. Together, these results provide biomechanical evidence of spinal column damage during high-cycle low-load low-angle loading.

12.
J Med Chem ; 59(17): 7773-82, 2016 09 08.
Article in English | MEDLINE | ID: mdl-27347692

ABSTRACT

SHP2 is a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also purportedly plays an important role in the programmed cell death pathway (PD-1/PD-L1). Because it is an oncoprotein associated with multiple cancer-related diseases, as well as a potential immunomodulator, controlling SHP2 activity is of significant therapeutic interest. Recently in our laboratories, a small molecule inhibitor of SHP2 was identified as an allosteric modulator that stabilizes the autoinhibited conformation of SHP2. A high throughput screen was performed to identify progressable chemical matter, and X-ray crystallography revealed the location of binding in a previously undisclosed allosteric binding pocket. Structure-based drug design was employed to optimize for SHP2 inhibition, and several new protein-ligand interactions were characterized. These studies culminated in the discovery of 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine (SHP099, 1), a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor.


Subject(s)
Antineoplastic Agents/chemistry , Piperidines/chemistry , Protein Tyrosine Phosphatase, Non-Receptor Type 11/antagonists & inhibitors , Pyrazines/chemistry , Pyrimidines/chemistry , Administration, Oral , Allosteric Regulation , Allosteric Site , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Crystallography, X-Ray , Drug Design , Female , Heterografts , High-Throughput Screening Assays , Humans , Male , Mice, Inbred C57BL , Mice, Nude , Models, Molecular , Neoplasm Transplantation , Piperidines/chemical synthesis , Piperidines/pharmacokinetics , Piperidines/pharmacology , Protein Conformation , Protein Tyrosine Phosphatase, Non-Receptor Type 11/chemistry , Pyrazines/chemical synthesis , Pyrazines/pharmacokinetics , Pyrazines/pharmacology , Pyrimidines/chemical synthesis , Pyrimidines/pharmacokinetics , Pyrimidines/pharmacology , Structure-Activity Relationship
13.
Eur J Pharm Sci ; 41(1): 23-30, 2010 Sep 11.
Article in English | MEDLINE | ID: mdl-20553863

ABSTRACT

Salt screening and selection is a well established approach for improving the properties of drug candidates, including dissolution rate and bioavailability. Typically during early development only small amounts of compound are available for solid state profiling, including salt screening. In order to probe large areas of experimental space, high-throughput screening is utilized and is often designed in a way to search for suitable crystallization parameters within hundreds or even thousands of conditions. However, the hit rate in these types of screens can be very low. In order to allow for selection of a salt form early within the drug development process whilst using smaller amounts of compounds, a screening procedure taking into account the compounds properties and the driving forces for salt formation is described. Experiments were carried out on the model compounds clotrimazole, cinnarizine itraconazole and atropine. We found an increase in crystalline hit rate for water-insoluble drugs crystallized from solutions that included at least 10% aqueous content. Conversely it was observed that compounds with greater water solubility did not benefit from aqueous content in salt screening, instead organic solvents lead to more crystalline screening hits. Results from four model compounds show that the inclusion of an aqueous component to the salt reaction can enhance the chance of salt formation and significantly improve the crystalline hit rate for low water soluble drugs.


Subject(s)
Pharmaceutical Preparations/chemistry , Salts/chemistry , Water/analysis , Crystallization , Crystallography, X-Ray , Models, Molecular , Solubility
14.
Mol Pharm ; 5(6): 946-55, 2008.
Article in English | MEDLINE | ID: mdl-19434850

ABSTRACT

Amorphous solids and crystalline salts are both of interest as a means of improving the dissolution characteristics and apparent solubility of poorly water soluble active pharmaceutical ingredients which have low bioavailability in humans. The theory and selection of both crystalline drug substance salt forms and amorphous products have been extensively studied. However, less is known about the impact of different counterions on the properties of amorphous drug substance salts. In this study, several salts of either nicardipine or propranolol were prepared and characterized with respect to glass transition temperature, crystallization tendency and moisture sorption behavior. Although the moisture sorption behavior and crystallization tendency varied depending on the counterion used, no trends were readily apparent. The glass transition temperature was found to be dependent on the counterion used to form the salt, and was higher in all instances for the salts than for the neutral compound. Several molecular descriptors were calculated for the various counterions, and multivariate analysis was used to build a model that successfully correlated Tg with a number of these parameters. Important parameters which influenced Tg included counterion pKa and electrophilicity index. In conclusion, it is apparent that, as for crystalline salts, the counterion has an effect on the properties of amorphous materials.


Subject(s)
Nicardipine/chemistry , Organic Chemicals/chemistry , Pharmaceutical Preparations/chemistry , Propranolol/chemistry , Salts/chemistry , Adsorption , Chemistry, Pharmaceutical , Crystallization , Glass/chemistry , Humans , Humidity , Molecular Structure , Multivariate Analysis , Solubility , Technology, Pharmaceutical/methods , Temperature , Transition Temperature , Water/chemistry
15.
J Am Chem Soc ; 126(41): 13347-53, 2004 Oct 20.
Article in English | MEDLINE | ID: mdl-15479091

ABSTRACT

The polymorphism of the simple amino acid glycine has been known for almost a century. It is also known that in aqueous solutions, at the isoelectric point (pI 5.9), the metastable alpha polymorph crystallizes, while the stable gamma form of glycine only nucleates at high and low pH. Despite the importance of understanding the process by which crystals nucleate, the solution and solid-state chemistry underlying this simple observation have never been explored. In this contribution, we have combined solution chemistry, crystallization, and crystallographic data to investigate the mechanisms by which this effect occurs. It is concluded that solution speciation and the consequent interactions between charged species and developing crystal nuclei determine the structural outcome of the crystallization process.


Subject(s)
Glycine/chemistry , Crystallization , Ethylenediamines/chemistry , Hydrogen-Ion Concentration , Malonates/chemistry , Models, Molecular , Solutions
SELECTION OF CITATIONS
SEARCH DETAIL
...